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Background: Trial of noninvasive ventilation (NIV) in the emergency department (ED) for
heterogeneous acute respiratory failure (ARF) has been optional and its clinical benefit
unclear.
Methods: We conducted a retrospective cohort study comparing between two periods, October
2001eSeptember 2003 and October 2004eSeptember 2006, i.e., before and after adopting an
NIV-trial strategy in which NIV was applied in the ED to any noncontraindicated ARF patients
needing ventilatory support and was then continued in the intermediate-care-unit. During these
two periods, we retrieved cases of ARF treated either invasively or with NIV, and compared the
patients’ in-hospital mortalities and the length of ICU and intermediate-care-unit stay.
Results: Compared were 73 (invasive 56, NIV 17) and 125 cases (invasive 31, NIV 94) retrieved
from 271 and 415 emergent admissions with proper pulmonary etiologies for mechanical ventila-
tion, respectively. Of their respiratory failures, type (hypercapnic/non-hypercapnic, 0.97 vs.
0.98) and severity (pH 7.23 vs. 7.21 for hypercapnic; PaO2/FiO2 133 vs. 137 for non-hypercapnic)
were similar, and the rate of predisposing etiologies was not significantly different. However,
excluding those with recurrent aspiration pneumonia for whomNIVwasmostly used as ‘‘ceiling’’
treatment, significant reductions in both overall in-hospital mortality (38%e19%, risk ratio 0.51,failure; Bilevel-PAP, bilevel positive airway pressure; CPAP, continuous positive airway pressure; DNI,
rtment; NIV, noninvasive ventilation; PEEP, positive end-expiratory pressure.
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68 K. Tomii et al.95% CI 0.31e0.84), and median length of ICU and intermediate-care-unit stay (12 vs. 5 days,
P< 0.0001) were found.
Conclusions: NIV-trial in the ED for all possible patients with ARF of pulmonary etiologies,
excluding those with recurrent aspiration pneumonia, may reduce overall in-hospital mortality
and ICU stays.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Noninvasive ventilation (NIV) is now the first-line treatment
for acute respiratory failure (ARF) of certain types of
pathogenesis such as COPD,1 cardiogenic pulmonary
edema, 2 and hypoxic respiratory failure associated with
immunodeficiency,3,4 and abundant evidence has been
presented of decreasing mortality rates,1,2 intubations,1,2
complications and ICU stays.5 The application of NIV for
other diagnoses is, however, still equivocal and not rec-
ommended routinely, although trials using patients with
pneumonia,6,7 hypoxic respiratory failure,8 bronchial
asthma,9 other types of hypercapnic failure10 and those
with do-not-intubate (DNI) orders11,12 suggest its validity.
Early use of NIV in the emergency department (ED) was
revealed to improve physiological variables rapidly, and
reduced mortality, ICU admissions for COPD13 and cardio-
genic pulmonary edema.14 Likewise, for other etiologies,
the immediate provision of continuous positive airway
pressure (CPAP) or positive end-expiratory pressure (PEEP)
can prevent atelectasis and subsequent V/Q mismatch
causing poorer oxygenation, while Bilevel-PAP or pressure
support can prevent further fatigue of respiratory muscles.
Additionally, in clinical practice, predisposing etiologies of
ARF are often complex and not easy to determine in a short
time. Therefore, if provided promptly in the ED regardless
of etiologies, NIV may produce certain benefits for both ARF
patients and acute care hospitals.15
In order to perform NIV in the ED, we have to find some-
where it is possible to continue treatment after the ED. A
typical ICU does not seem to be suitable for this, because the
capacity of such units is usually insufficient and, further-
more, the cost to treat every patient is too high. Additionally,
assignment to the ICU is unnecessary for not a few patients
with DNI orders, who, in some cases, are good candidates for
NIV. Recently, the number of reports on performing NIV
outside the ICU is increasing,16,17 and experience in inter-
mediate-care-units has provided favorable outcomes, as
well as being cost-effective.15,18,19 Thus, prompt initiation in
the ED with subsequent continuation in intermediate-care-
units, which may be quite common in some countries,19
seems to be the optimal location for NIV for ARF.
Based on the above details, we have been initiating NIV
(prompt bi-level PAP or CPAP) in the ED and continuing it in
the intermediate-care-unit for every possible non-
contraindicated patient with ARF needing ventilatory
support since 2004. In order to elucidate the benefits of this
strategy, we retrospectively compared the mortality rates
and the length of ICU or intermediate-care-unit stay among
ARF admissions to our hospital with invasive ventilation or
NIV during the periods before and after the introduction of
the NIV-trial strategy.Methods
Application and location of noninvasive ventilation
In our 900-bed community teaching hospital, which plays
a central role in treating emergent patients from Kobe
City’s population of 1,560,000 people, NIV for ARF was fully
introduced in the ED in 2004, without additional staffing
with nurses and respiratory therapists. Thereafter, bi-level
PAP or CPAP by ‘‘BiPAP Vision’’ (Respironics, Inc.), which
has a high-flow oxygen blender allowing FiO2 up to 100%,
became available at anytime. Before that time, NIV had
been performed only in some patients with acute on
chronic hypercapnic failure, and most patients who needed
mechanical ventilation were intubated. In contrast, after
that time, NIV-trial strategy was applied, namely, NIV could
be begun at any time in any patients with ARF needing
mechanical ventilation, as long as they had no contraindi-
cations to NIV such as respiratory arrest, hemodynamic
instability and/or urgent need for airway management. All
the patients, whether in pre- or in post-NIV trial strategy, to
whom NIV had been already applied, or would be applied
soon were transferred from emergency room to a preexist-
ing intermediate-care-unit within the ED, which had been
providing a 4:1 nurse to patient ratio per shift, adequate
continuous non-invasive monitoring and the availability of
a physician 24 h a day. In the case of NIV failure, they were
intubated and could be transferred to the ICU. However, if
they were stabilized by NIV, they would either stay there
until the treatment was completed, or were transferred to
the general wards if they had no urgent need for intubation
or if they had DNI orders. In the case of patients with acute
on chronic respiratory failure for whom home NIV had
previously been prescribed, we used the same ventilator in
hospital as long as they could be managed without a high
FiO2 setting.Data collection and statistics
Data collection and analysis were processed only by our
authors without exposing patient’s personal information to
other people. As this was a retrospective historical control
study, our IRB stated that their approval was not necessary.
For the two 2-year periods, October 2001eSeptember
2003 and October 2004eSeptember 2006, i.e., before and
after the introduction of NIV-trial strategy for ARF patients,
we screened all the medical records of pulmonary emergent
admissions to our hospital and retrieved cases of ARF iden-
tified as those needing oxygenation on admission defined as
PaO2< 60 mmHg, or SpO2< 90% on room air (Fig 1). In the
case of acute exacerbation of chronic respiratory failure, we
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maintain SpO2> 90%. During the former period, 271 cases
were retrieved from a total of 485 cases by excluding those
unsuitable for survival analysis or for NIV-candidates;
malignancy, cardiopulmonary arrest, those who needed
urgent airway management, namely, asphyxia, airway nar-
rowing, inhalationburn, airway trauma,massivehemoptysis,
drug overdose, and those in whom prognosis would not be
affected by ventilatory management, namely, pneumo-
thorax, massive pleural effusion and pulmonary embolism.
Similarly, 415 cases were retrieved from 859 records during
the latter period. Finally, excluding cases with no need or
intention for mechanical ventilation under the each strategy
of the both periods, 73 and 125 caseswere used for this study.
Their demographic data, types of respiratory failure defined
as ‘‘hypercapnic’’ (PaCO2> 45 torr on admission) and ‘‘non-
hypercapnic’’ (P/F< 300 and PaCO2< 45 torr on admission),
predisposing etiologies, in-hospital mortality, length of ICU
and intermediate-care-unit stay, and the total number of
hospital days were compared between the two periods.
The type ofmechanical ventilation appliedwas defined as
follows: (1) invasive: every case in which invasive ventilation
was used, (2) NIV: cases, in which NIV was used without
changing to invasive ventilation. The cases we retrieved
were tentatively classified into six categories depending on
their pulmonary etiologies of ARF based on their medical
records: (1) pneumonia (recurrent aspiration pneumonia,
such as totally bed-ridden, unable to swallow, and having
multiple aspiration episodes, were separated from otherEmergent admissions wit
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which the same previously prescribed home-NPPV machine was us
bation had been performed before arrival in eight cases. Emerge
airway (4), cardiovascular instability (3), deep coma (5), and unsppneumonia because their indication for mechanical venti-
lation and ICU stay were generally different from those with
other etiologies), (2) interstitial lung disease, (3) other types
of non-hypercapnic respiratory failure such as alveolar
hemorrhage, congestive heart failure, ARDS, pulmonary
vasculitis and their coexistence, (4) bronchial asthma, (5)
COPD and (6) other types of hypercapnic respiratory failure
such as old pulmonary tuberculosis, deformed thorax,
bronchiectasis, sarcoidosis and pulmonary Aspergillosis.
Unfortunately, as our data source was limited to the medical
records of the department of respiratory medicine, cases
with congestive heart failure and extra-pulmonary ARDS
were largely excluded. Cases considered to have both COPD
and asthma were included under ‘‘COPD’’ when their ARF
was hypercapnic, and under ‘‘bronchial asthma’’ when non-
hypercapnic. Cases of COPD with pulmonary infiltrates were
included under ‘‘pneumonia’’, as were those of ARDS
complicated with pneumonia.
In comparing the two periods, we used unpaired-t tests
for continuous data: patient’s age, pH, PaO2/FiO2 ratio,
length of stay in the ICU, intermediate-care-unit and
hospital, and chi-square tests for categorical data: gender
ratio, diagnosis (dfZ 5). The risk ratio of in-hospital
mortality and that of ICU and intermediate-care-unit use
(total days in the ICU and intermediate-care-unit per stay in
hospital) were presented with a 95% confidence interval.
Discharge rates from the ICU and intermediate-care-unit
were expressed by the KaplaneMeier method and the
difference was examined by Logrank test, in which datah ARF of pulmonary etiologies
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statistical analyses were performed using statistical soft-
ware (JMP 7.0.2.; SAS Institute Inc.).
Results
The number of cases in which mechanical ventilation, inva-
sive or noninvasive, was administered was 56 and 17 in the
period ‘‘before introduction’’ and 31 and 94 cases in the
‘‘after introduction’’, respectively (Table 1). Patient ages
were similar overall (68.9 13.0 vs. 71.2 13.6, PZ 0.23),
but significantly lower in those treated with invasive venti-
lation than in those with NIV in the period ‘‘before intro-
duction’’ (PZ 0.01). Gender ratio (percentages of male;
63.0 vs. 62.4, PZ 0.93) and the type of respiratory failure
were similar (hypercapnic/non-hypercapnic; 0.97 vs. 0.98).
Mean pH in hypercapnic failures indicating their severity,
was not statistically different between the two periods
(7.23 0.14 vs. 7.21 0.12, PZ 0.47), but significantly
lower in those treated with invasive ventilation than in those
with NIV in the period ‘‘after introduction’’ (P< 0.0001).
The ratio of PaO2/FiO2 in non-hypercapnic failures was not
different between the two periods (133 69 vs. 137 66,
PZ 0.83). In terms of the rate of pulmonary etiologies
causing ARF, no statistical difference existed between the
two periods (pneumonia 39.7% vs. 34.4%, bronchial asthma
13.7% vs. 9.6%, other hypercapnic respiratory failure 24.7%
vs. 24.0%, interstitial lung disease 9.6% vs. 15.2%, COPD 8.2%
vs. 16.0%, other non-hypercapnic failure 4.1% vs. 0.8%)
(PZ 0.07). The rate of patients who died after refusing
invasive ventilation and underwent NIV as ‘‘ceiling’’ treat-
ment, was similar (4/17; 23.5% vs. 23/94; 24.5%) but their
types of respiratory failure shifted from hypercapnic to non-
hypercapnic (hypercapnic/non-hypercapnic; from 2/1 to 5/
14) and their predisposing etiologies from ‘‘other hyper-
capnic failure’’ to ‘‘recurrent aspiration pneumonia’’ and
‘‘interstitial lung disease’’.
Overall in-hospital mortality rates decreased from
‘‘before introduction’’ to ‘‘after introduction’’ (38%e25%,
risk ratio 0.65; 95% CI 0.42e0.99) (Table 2), in which
hypercapnic failures favored the tendency more than non-
hypercapnic failures. The reduction in mortality rates
slightly differed among the etiologies, with those of
‘‘bronchial asthma’’, ‘‘other hypercapnic respiratory
failure’’, ‘‘interstitial lung disease’’ and ‘‘COPD’’ showing
a conspicuous risk ratio of 0.20e0.60 and statistical signif-
icance existed in ‘‘other hypercapnic failure’’ and ‘‘inter-
stitial lung disease’’ despite including not a few patients
with DNI orders. As for ‘‘pneumonia’’, which was the most
frequent etiology, the in-hospital mortality rate did not
improve after the introduction of NIV-trial, especially in
‘‘recurrent aspiration pneumonia’’. Had we excluded cases
in this category from the overall analysis, the mortality rate
would have been 25/66 (38%) and 20/104 (19%) before and
after ‘‘introduction’’, respectively, and the risk ratio
between them would have been 0.51 (95% CI 0.31-0.84), in
spite of a similar degree of severity in their respiratory
failure (pH 7.23 0.14 vs. 7.23 0.11, PZ 0.86 for hyper-
capnic; and PaO2/FiO2 123 62 vs. 142 64, PZ 0.23 for
non-hypercapnic).
Although the total length of hospital stay, excluding
those of recurrent aspiration pneumonia, was almost thesame for the two periods (17.8 14.8 vs. 17.7 15.4,
PZ 0.91), the length of ICU and intermediate-care-unit
stays decreased (8.0 9.1 days vs. 5.6 4.4 days,
PZ 0.01). Discharge rates from the ICU and intermediate-
care-unit (Fig. 2) were significantly higher in the period
‘‘after introduction’’ than in the period ‘‘before introduc-
tion’’ (median length of stay; 12 vs. 5 days, P< 0.0001), and
the rate of ICU and intermediate-care-unit use (total days
in the ICU and intermediate-care-unit per stay in hospital)
decreased overall from 620/1306 (47.5%) to 583/2485
(23.5%), risk ratio 0.49 (95% CI 0.45-0.54).
Discussion
In association with the introduction of NIV-trial strategy,
both an overall significant reduction in in-hospital mortality
and use of the ICU and intermediate-care-unit were seen in
emergent admissions to our hospital of patients with ARF of
various pulmonary etiologies. To the best of our knowledge,
this is the first report indicating the overall benefits
obtained after introduction of NIV in treating ARF regard-
less of etiologies in clinical practice.
Reduction in mortality by NIV has been reported for
several diagnoses; relative risk of 0.52 for acute exacerba-
tion of COPD1 and 0.55 for acute cardiogenic pulmonary
edema frommeta-analysis,2 0.46 (ICUmortality, 18% vs. 39%)
for heterogeneous severe hypoxemic failure7 and 0.11 (ICU
mortality, 6% vs. 53%) for early ARDS in experienced hospi-
tals.8 Nevertheless, for other etiologies such as pneumonia,
interstitial lung disease, bronchial asthma, mortality
reduction by NIV has not yet been presented. Therefore, our
data showing an overall reduction in mortality of heteroge-
neous predisposing etiologies is both noteworthy and also
useful in promoting NIV in the clinical practice of the ED,
where the etiologies of ARF are not always easy to determine
in a short period of time, and where no time should be lost.
The overall reduction in mortality could have been due
to the common beneficial factors of NIV for all etiologies,
such as early administration of PEEP or pressure support,
which could have prevented further worsening of ARF by
increasing pulmonary gas exchange and/or reducing the
work of breathing.20 The application of NIV for patients
with DNI orders11 might also have been a contributing factor
in decreased mortalities as seen in our study in ‘‘interstitial
pneumonia’’; however, the actual percentage of rescued
DNI patients could not be obtained from this retrospective
study. Conversely, patients with DNI orders for whom NIV
was performed as ‘‘ceiling’’ treatment, should have
diminished the effect of mortality reduction, because those
who were in the same unfavorable condition had not been
included in the period ‘‘before introduction of NIV-trial’’.
This seems to be the main reason why overall mortality
reduction was conspicuous after excluding those with
recurrent aspiration pneumonia.
Although NIV itself has the potential to reduce ICU stay
by lowering the rate of intubation and complications such
as ventilator associated pneumonia,21,22 the strategy of
performing NIV in the intermediate-care-unit instead of the
ICU can reduce ICU stay further. Similarly, the subsequent
transfer of low-risk patients, such as intermittent users of
NIV, from the intermediate-care-unit to the general ward
will reduce the length of their stay. These patient-flows,
Table 1 Baseline characteristics of cases that underwent mechanical ventilation in the two periods.
Characteristic Before introduction of ‘‘NIV-trial’’ (Oct 2001eSep 2003) After introdu tion of ‘‘NIV-trial’’ (Oct 2004eSep 2006)
Invasive NIV Total Invasive NIV Total
No. of cases 56 17 (4) 73 31 94 (23) 125
Age, mean SD years 66.8 12.7a 75.8 11.9 68.9 13.0 69.5 17.2 71.8 12.3 71.2 13.6
M/F ratio (male %) 66.1 52.9 63.0 58.1 63.8 62.3
Types of respiratory failures
Hypercapnic failure (PaCO2> 45 torr) 18 14 (2) 32 11 47 (5) 58
pH 7.22 0.17 7.26 0.11 7.23 0.14 7.10 0.16b 7.24 0.09 7.21 0.12
Non-hypercapnic failure
(P/F< 300 and PaCO2< 45 torr)
31 2 (1) 33 16 43 (14) 59
PaO2/FiO2 133 69 e 133 69 118 56 143 69 137 66
Others not specifiedc 7 1 (1) 8 4 4 (4) 8
Diagnosis
Pneumonia, total 25 4 (1) 29 (39.7%) 17 26 (9) 43 (34.4%)
Recurrent aspiration pneumonia 5 2 (1) 7 (9.6%) 10 11 (7) 21 (16.8%)
Other pneumonia 20 2 22 (30.1%) 7 15 (2) 22 (17.6%)
Bronchial asthma 9 1 10 (13.7%) 4 8 12 (9.6%)
Other hypercapnic failure 8 10 (3) 18 (24.7%) 4 26 (2) 30 (24.0%)
Interstitial lung disease 7 0 7 (9.6%) 2 17 (10) 19 (15.2%)
COPD 4 2 6 (8.2%) 4 16 (1) 20 (16.0%)
Other non-hypercapnic failure 3 0 3 (4.1%) 0 1 (1) 1 (0.8%)
() Denotes the number of patients who died after refusing invasive ventilation and undergoing NIV as ‘‘ceiling’’ treatment.
a Mean age of those who had invasive ventilation was significantly lower than those who underwent NIV in the period ‘‘before i tro-
duction of NIV-trial’’ (PZ 0.01).
b Mean pH of hypercapnic failures was significantly lower in those who had invasive ventilation than in those who underwent NIV i the
period ‘‘after introduction of NIV-trial’’ (PZ 0.0007).
c Types of respiratory failure were not specifically defined by the patient’s medical record.
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Table 2 In-hospital mortality rates of retrieved cases of ARF that underwent invasive ventilation or NIV.
Before introduction
of ‘‘NIV-trial’’
(Oct 2001eSep 2003)
After introduction
of ‘‘NIV-trial’’
(Oct 2004eSep 2006)
Risk ratio
(95%CI)
Overall (%) 28/73 (38) 31/125 (25) 0.65 (0.42e0.99)
Hypercapnic failures (%) 7/32 (22) 7/58 (12) 0.55 (0.21e1.43)
Non-hypercapnic failures (%) 16/33 (49) 20/59 (34) 0.70 (0.42e1.15)
Pneumonia, total (%) 11/29 (38) 16/43 (37) 0.98 (0.54e1.78)
Recurrent aspiration pneumonia (%) 3/7 (43) 11/21 (52) 1.22 (0.47e3.15)
Other pneumonia (%) 8/22 (36) 5/22 (23) 0.63 (0.24e1.61)
Bronchial asthma (%) 2/10 (20) 1/12 (8) 0.38 (0.04e3.67)
Other hypercapnic failure (%) 6/18 (33) 2/30 (7) 0.20 (0.05e0.89)
Interstitial lung disease (%) 7/7 (100) 9/19 (47) 0.47 (0.29e0.76)
COPD (%) 1/6 (17) 2/20 (10) 0.60 (0.07e5.53)
Other non-hypercapnic failure (%) 1/3 (33) 1/1 (100) 3.00 (0.61e14.9)
Overall excluding recurrent
aspiration pneumonia (%)
25/66 (38) 10/104 (19) 0.51 (0.31e0.84)
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Figure 2 Discharge rates from the ICU and Intermediate-
care-unit. Discharge rates were significantly higher in the
period ‘‘after introduction of NIV-trials’’ than in the period
‘‘before introduction’’ (median length of stay; 5 vs, 12 days,
P< 0.0001). This statistical analysis was performed excluding
cases of recurrent aspiration pneumonia.
72 K. Tomii et al.based on the idea that the appropriate site for NIV should
be decided according to the situation in each country and
each hospital,18 seem to be realistic when it comes to
performing NIV widely as the first-line treatment for ARF.
Conversely, strict adherence to the ICU for NIV might limit
its immediate application, loses the chance to avoid intu-
bation and thereby increase ICU use.
In terms of the rate of classified etiologies, which was
tentatively done according to medical records, COPD was
unexpectedly low. This might have been due to the classifi-
cation of complicated cases; for example, acute exacerba-
tion with lung infiltration was included under ‘‘pneumonia’’,
while those with other coincidental disease such as chest
wall deformities or old pulmonary tuberculosis were allo-
cated to ‘‘other hypercapnic failure’’. Similarly, ARDS,which
was to be included under ‘‘other non-hypercapnic failure’’,
was remarkably low, probably because most of the patients
with extrapulmonary ARDSwere originally excluded from the
medical records of our department, and a considerable
number of cases of pulmonary ARDS were included in the
category ‘‘interstitial lung disease’’ or ‘‘pneumonia’’.
Once we had introduced the NIV-trial strategy, the rate
of NIV in the total mechanical ventilation increased
remarkably from 20 to 30% e comparable to the usual level
reported23 e to almost 80%. This rapid increase of NIV
seems to have been caused by several components of our
strategy: (1) the ready availability of NIV machines with
a high oxygen blender, which enabled immediate pressure
support and PEEP with high FiO2; (2) the presence of
a physician at initiation and observation of NIV during the
acute phase; and (3) smooth transfer of the patients from
the ICU and intermediate-care-unit to general wards. In
addition, although no extra nursing staff or respiratory
therapists were provided, an associated accumulation of
experience and confidence makes the indication wider and
produces a favorable outcome as reported.21 We think
these factors are prerequisites for introducing NIV in the ED
successfully into the clinical practice of a community
hospital.There were certain limitations in this study. As this was
a retrospective historical control study, differences existed
in the background of the cases in the two periods. Several
confounding factors such as changes in the number of
patients, drugs, members of staff and monitoring equip-
ment from 2001e2003 to 2004e2006 may possibly have
influenced the results, although the rate of the type of
respiratory failure and each category of the predisposing
etiology were not significantly different. Another limitation
in this study was the highly selected study populations.
Although many patients were excluded for various reasons
until the study population consisted of 15% and 14% of
patients with acute respiratory failure in the pre- and post-
NIV trial strategy groups, respectively, this population
comprised most of the pulmonary etiologies that could be
rescued by mechanical ventilation without caring for
Noninvasive ventilation trial for various types of ARF in the ED 73airway patency. The small numbers might inhibit the reli-
ability of our results; however, this grouping of the patients
would be presumably justifiable in the urban clinical situ-
ation in one hospital. Although we could not include
congestive pulmonary edema, the result would not be
affected much because NIV is considered to be favorable
for this etiology. In our NIV-trial strategy, we tried NIV in
every patient by physician’s decision as needing mechanical
ventilation without definite contraindication, however, if
the more accurate definition of the NIV-indications, i.e.,
pCO2 of 45e55, 55e65 etc. or pH 7.35e7.3, 7.3e7.25 etc.
could be obtained, it would be better and helpful for
applying this strategy. In terms of ICU use, the increased
number of patients admitted emergently might have
affected the results, as the increased numbers might have
created other pressures to expel simple ARF patients from
the ICU.
In conclusion, the NIV-trial strategy for ARF including
quick and broad application of NIV in the ED, based on an
on-site physician’s decision and subsequent continuation in
the intermediate-care-unit, could have the effect of
reducing mortality and ICU use, especially if those with
debilitating conditions such as recurrent aspiration pneu-
monia are excluded. Obviously, cases needing cardiovas-
cular support or complicated ventilator settings should be
managed in the ICU with invasive ventilation; however, the
numerous remaining cases with simple pulmonary etiology
could be managed promptly and simply with NIV outside the
ICU such as in the ED, intermediate care unit and general
wards. This separation of roles can save more lives, save
space, and also, presumably, cost, especially in hospitals
where ICU resources are always limited.
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